Idorsia announces changes to Idorsia Executive Committee and Board of Directors
21 mai 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board – taking...
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
21 mai 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board – taking...
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
21 mai 2024 00h50 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights ...
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
21 mai 2024 00h50 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights ...
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
21 mai 2024 00h40 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of...
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
21 mai 2024 00h40 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of...
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
14 mai 2024 11h45 HE
|
Idorsia Pharmaceuticals Ltd
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same...
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
14 mai 2024 11h45 HE
|
Idorsia Pharmaceuticals Ltd
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same...
Bondholders approve amended terms of the 2024 convertible bonds
06 mai 2024 12h35 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the...
Bondholders approve amended terms of the 2024 convertible bonds
06 mai 2024 12h35 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Bondholders approve amended terms of the 2024 convertible bonds The proposed amendments to the terms of the 2024 convertible bond have been approved by the...